The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
Abstract
Letters6 September 2011Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss SyndromeFrank Moosig, MD, PhD, Wolfgang Ludwig Gross, MD, PhD, Kristina Herrmann, MD, Jan Phillip Bremer, MD, and Bernhard Hellmich, MD, PhDFrank Moosig, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Wolfgang Ludwig Gross, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Kristina Herrmann, MDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., Jan Phillip Bremer, MDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany., and Bernhard Hellmich, MD, PhDFrom University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-5-201109060-00026 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This article has been corrected. The original version (PDF) is appended to this article as a supplement.Background: Hypereosinophilia plays a critical role in the pathogenesis of the Churg–Strauss syndrome. Interleukin-5 (IL-5) is the most potent inducer of maturation and activation of eosinophils. We demonstrated elsewhere (1) that IL-5 production is increased in the Churg–Strauss syndrome and that interferon-α therapy, which downregulates IL-5 production, can induce remission of this condition (2). However, long-term results with interferon-α and other biological and conventional drugs, such as cyclophosphamide, have been disappointing.Frequent relapses, the need for long-term medium- to high-dose glucocorticosteroid therapy, and ...References1. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121-31. [PMID: 16126951] CrossrefMedlineGoogle Scholar2. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129:370-4. [PMID: 9735064] LinkGoogle Scholar3. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-28. [PMID: 18344568] CrossrefMedlineGoogle Scholar4. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336-43. [PMID: 20513524] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Lübeck and Clinic Bad Bramstedt, 24576 Bad Bramstedt, Germany, and University of Tübingen and Hospital Plochingen, 73207 Tübingen, Germany.Disclosures: This study was financially supported by GSK, and GSK provided the study medication. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInterferon-α Treatment of Four Patients with the Churg-Strauss Syndrome Efstratios Tatsis , Armin Schnabel , and Wolfgang L. Gross Correction: Targeting Interleukin-5 in Refactory and Releasing Churg-Strauss Syndrome Metrics Cited byEGPA Phenotyping: Not Only ANCA, but Also EosinophilsA Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with PolyangiitisManagement of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two CasesEosinophile Granulomatose mit PolyangiitisPerspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With PolyangiitisFrom DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseasesMepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyPulmonale Manifestationen von VaskulitidenResponse to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitisEosinophilic granulomatosis with polyangiitisMepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case seriesNovel Targets for Drug Use in Eosinophilic Granulomatosis With PolyangiitisSteroid alternatives for managing eosinophilic lung diseasesLessons learned from targeting eosinophils in human diseaseMepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumabKorti
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Cited by
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D., Khoury, P., Klion, A., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,094
Self-citationGroh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476
Self-citationEmmi, G., Bettiol, A., Gelain, E., Bajema, I. M., Berti, A., Burns, S., Cid, M. C., Cohen Tervaert, J. W., Cottin, V., Durante, E., et al. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00958-w · Cited by 334
Self-citationGreco, A., Rizzo, M. I., De Virgilio, A., Gallo, A., Fusconi, M., Ruoppolo, G., Altissimi, G., & De Vincentiis, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.004 · Cited by 293
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art
Vaglio, A., Buzio, C., & Zwerina, J. (2013) · Allergy · doi:10.1111/all.12088 · Cited by 284
Metadata
- Authors
- Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P., & Hellmich, B.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2011-09-06
- Volume
- 155
- Issue
- 5
- Pages
- 341-343
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1992648705
- Cited by
- 206
- References
- 1
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome. https://app.cochat.ai/papers/10.7326/0003-4819-155-5-201109060-00026
- The paper
- Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P., & Hellmich, B. (2011). Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-155-5-201109060-00026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.